 | • レポートコード：MRC2304A210 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、250ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に278.0億ドルであった世界の抗腫瘍薬市場規模が2022年に311.3億ドルに到達し、2027年までにCAGR 12.14％で成長して553.0億ドルへと拡大すると予測しています。当調査資料では、抗腫瘍薬の世界市場について多角的な視点から分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患別（乳がん、白血病、肺がん、メラノーマ、前立腺がん）分析、投与経路別（筋肉内、腹腔内、静脈内、脳室内/髄腔内、膀胱内）分析、薬剤別（アルキル化剤、代謝拮抗剤、抗腫瘍抗生物質、有糸分裂阻害剤、トポイソメラーゼ阻害剤）分析、エンドユーザー別（クリニック、病院、専門センター）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめました。なお、当書内の企業情報としては、AstraZeneca plc、Bayer AG、Biogen Inc.、Bristol-Myers Squibb、Celgene Corporation、Eisai Co., Ltd.、F. Hoffmann-La Roche AG、Johnson & Johnson、Merck & Co., Inc.、Novartis International AG、Otsuka Pharmaceutical Co., Ltd.、Pfizer Inc.、Sanofi S.A.、Takeda Pharmaceutical Company Limitedなどが掲載されています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の抗腫瘍薬市場規模：疾患別 - 乳がんにおける市場規模 - 白血病における市場規模 - 肺がんにおける市場規模 - メラノーマにおける市場規模 - 前立腺がんにおける市場規模 ・世界の抗腫瘍薬市場規模：投与経路別 - 筋肉内投与薬の市場規模 - 腹腔内投与薬の市場規模 - 静脈内投与薬の市場規模 - 脳室内/髄腔内投与薬の市場規模 - 膀胱内投与薬の市場規模 ・世界の抗腫瘍薬市場規模：薬剤別 - アルキル化剤の市場規模 - 代謝拮抗剤の市場規模 - 抗腫瘍抗生物質の市場規模 - 有糸分裂阻害剤の市場規模 - トポイソメラーゼ阻害剤の市場規模 ・世界の抗腫瘍薬市場規模：エンドユーザー別 - クリニックにおける市場規模 - 病院における市場規模 - 専門センターにおける市場規模 ・世界の抗腫瘍薬市場規模：地域別 - 南北アメリカの抗腫瘍薬市場規模 アメリカの抗腫瘍薬市場規模 カナダの抗腫瘍薬市場規模 ブラジルの抗腫瘍薬市場規模 ... - アジア太平洋の抗腫瘍薬市場規模 日本の抗腫瘍薬市場規模 中国の抗腫瘍薬市場規模 インドの抗腫瘍薬市場規模 韓国の抗腫瘍薬市場規模 台湾の抗腫瘍薬市場規模 ... - ヨーロッパ/中東/アフリカの抗腫瘍薬市場規模 イギリスの抗腫瘍薬市場規模 ドイツの抗腫瘍薬市場規模 フランスの抗腫瘍薬市場規模 ロシアの抗腫瘍薬市場規模 ... - その他地域の抗腫瘍薬市場規模 ・競争状況 ・企業情報 |
The Global Anti-Tumor Drugs Market size was estimated at USD 27.80 billion in 2021 and expected to reach USD 31.13 billion in 2022, and is projected to grow at a CAGR 12.14% to reach USD 55.30 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Anti-Tumor Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Indications, the market was studied across Breast Cancer, Leukemia, Lung Cancer, Melanoma, and Prostate Cancer.
Based on Route of Administration, the market was studied across Intra-muscular, Intraperitoneal, Intravenous, Intraventricular / Intrathecal, Intravesicular, Oral, Subcutaneous, and Topical.
Based on Drug, the market was studied across Alkylating Agents, Antimetabolites, Antitumor Antibiotic., Mitotic Inhibitors, and Topoisomerase Inhibitors.
Based on Drug Class, the market was studied across . Hormonal Therapy, Cytotoxics, and Targeted Therapy. The Targeted Therapy is further studied across Monoclonal Antibodies and Small Molecule Inhibitors.
Based on End User, the market was studied across Clinics, Hospitals, and Specialty Centers.
Based on Distribution Channels, the market was studied across Hospital Pharmacies and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Anti-Tumor Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-Tumor Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-Tumor Drugs Market, including Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb, Celgene Corporation, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Anti-Tumor Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-Tumor Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-Tumor Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Anti-Tumor Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Anti-Tumor Drugs Market?
6. What is the market share of the leading vendors in the Global Anti-Tumor Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Anti-Tumor Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in incidence of cancer across the globe with the surge in the geriatric population
5.1.1.2. Growing awareness regarding early diagnosis and treatment for the cancer
5.1.1.3. Increase in expenditures on healthcare by government
5.1.2. Restraints
5.1.2.1. Unfavorable outcomes associated with the use of cancer drugs
5.1.3. Opportunities
5.1.3.1. Rise in the number of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
5.1.3.2. Emerging market growth potential in developing nations such as Asian and African economies
5.1.4. Challenges
5.1.4.1. High cost of anti-cancer drugs and low survival rate
5.2. Cumulative Impact of COVID-19
6. Anti-Tumor Drugs Market, by Indications
6.1. Introduction
6.2. Breast Cancer
6.3. Leukemia
6.4. Lung Cancer
6.5. Melanoma
6.6. Prostate Cancer
7. Anti-Tumor Drugs Market, by Route of Administration
7.1. Introduction
7.2. Intra-muscular
7.3. Intraperitoneal
7.4. Intravenous
7.5. Intraventricular / Intrathecal
7.6. Intravesicular
7.7. Oral
7.8. Subcutaneous
7.9. Topical
8. Anti-Tumor Drugs Market, by Drug
8.1. Introduction
8.2. Alkylating Agents
8.3. Antimetabolites
8.4. Antitumor Antibiotic.
8.5. Mitotic Inhibitors
8.6. Topoisomerase Inhibitors
9. Anti-Tumor Drugs Market, by Drug Class
9.1. Introduction
9.2. . Hormonal Therapy
9.3. Cytotoxics
9.4. Targeted Therapy
9.5.1. Monoclonal Antibodies
9.5.2. Small Molecule Inhibitors
10. Anti-Tumor Drugs Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Specialty Centers
11. Anti-Tumor Drugs Market, by Distribution Channels
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Retail Pharmacies
12. Americas Anti-Tumor Drugs Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Anti-Tumor Drugs Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Anti-Tumor Drugs Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Amgen Inc.
16.1.1. Business Overview
16.1.2. Key Executives
16.1.3. Product & Services
16.2. Astellas Pharma Inc.
16.2.1. Business Overview
16.2.2. Key Executives
16.2.3. Product & Services
16.3. AstraZeneca plc
16.3.1. Business Overview
16.3.2. Key Executives
16.3.3. Product & Services
16.4. Bayer AG
16.4.1. Business Overview
16.4.2. Key Executives
16.4.3. Product & Services
16.5. Biogen Inc.
16.5.1. Business Overview
16.5.2. Key Executives
16.5.3. Product & Services
16.6. Bristol-Myers Squibb
16.6.1. Business Overview
16.6.2. Key Executives
16.6.3. Product & Services
16.7. Celgene Corporation
16.7.1. Business Overview
16.7.2. Key Executives
16.7.3. Product & Services
16.8. Eisai Co., Ltd.
16.8.1. Business Overview
16.8.2. Key Executives
16.8.3. Product & Services
16.9. Eli Lilly and Company
16.9.1. Business Overview
16.9.2. Key Executives
16.9.3. Product & Services
16.10. F. Hoffmann-La Roche AG
16.10.1. Business Overview
16.10.2. Key Executives
16.10.3. Product & Services
16.11. Johnson & Johnson
16.11.1. Business Overview
16.11.2. Key Executives
16.11.3. Product & Services
16.12. Merck & Co., Inc.
16.12.1. Business Overview
16.12.2. Key Executives
16.12.3. Product & Services
16.13. Novartis International AG
16.13.1. Business Overview
16.13.2. Key Executives
16.13.3. Product & Services
16.14. Otsuka Pharmaceutical Co., Ltd.
16.14.1. Business Overview
16.14.2. Key Executives
16.14.3. Product & Services
16.15. Pfizer Inc.
16.15.1. Business Overview
16.15.2. Key Executives
16.15.3. Product & Services
16.16. Sanofi S.A.
16.16.1. Business Overview
16.16.2. Key Executives
16.16.3. Product & Services
16.17. Takeda Pharmaceutical Company Limited
16.17.1. Business Overview
16.17.2. Key Executives
16.17.3. Product & Services
16.18. Teva Pharmaceutical Industries Ltd.
16.18.1. Business Overview
16.18.2. Key Executives
16.18.3. Product & Services
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing